Advances and obstacles of T cell-based immunotherapy in gynecological malignancies
T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves genetically reprogramming T lymphocytes to recognize tumor-specific antigens, has shown clinical success in hematol...
Saved in:
| Published in | Molecular cancer Vol. 24; no. 1; pp. 207 - 25 |
|---|---|
| Main Authors | , , , |
| Format | Journal Article |
| Language | English |
| Published |
England
BioMed Central Ltd
26.07.2025
BioMed Central BMC |
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves genetically reprogramming T lymphocytes to recognize tumor-specific antigens, has shown clinical success in hematologic malignancies and is expanding its potential in solid tumors. Gynecological cancers, including ovarian, cervical, and endometrial carcinomas, present persistent therapeutic challenges due to their aggressive recurrence patterns and limited responses to conventional therapies in advanced disease stages. This review offers a comprehensive analysis of CAR-T cell therapy advancements in gynecologic oncology, examining fundamental biological mechanisms of tumor-immune interactions, clinical progress in target antigen validation, and innovative approaches to counter immunosuppressive tumor microenvironments. Key challenges specific to these malignancies are discussed, such as molecular heterogeneity in endometrial tumors, ascites-mediated T-cell dysfunction in ovarian cancer (OC), and viral antigen dynamics in HPV- driven cervical carcinomas. Recent clinical evidence shows improved therapeutic outcomes through optimized CAR architectures and preconditioning regimens, with objective response rates demonstrating progressive enhancement across successive clinical trial generations. The discussion addresses ongoing limitations regarding treatment durability and manufacturing consistency while exploring emerging solutions such as synthetic biology approaches and multi-omics guided antigen selection. By integrating preclinical insights with translational clinical data, this work establishes a strategic framework for advancing adoptive T-cell therapies in gynecologic oncology, emphasizing the synergistic potential of combining CAR-T technology with personalized neoantigen vaccines and microenvironment-reprogramming agents. These collective advances underscore the transformative prospects of engineered T-cell immunotherapies while providing actionable strategies to overcome the unique biological barriers inherent to female reproductive tract malignancies. |
|---|---|
| AbstractList | T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves genetically reprogramming T lymphocytes to recognize tumor-specific antigens, has shown clinical success in hematologic malignancies and is expanding its potential in solid tumors. Gynecological cancers, including ovarian, cervical, and endometrial carcinomas, present persistent therapeutic challenges due to their aggressive recurrence patterns and limited responses to conventional therapies in advanced disease stages. This review offers a comprehensive analysis of CAR-T cell therapy advancements in gynecologic oncology, examining fundamental biological mechanisms of tumor-immune interactions, clinical progress in target antigen validation, and innovative approaches to counter immunosuppressive tumor microenvironments. Key challenges specific to these malignancies are discussed, such as molecular heterogeneity in endometrial tumors, ascites-mediated T-cell dysfunction in ovarian cancer (OC), and viral antigen dynamics in HPV- driven cervical carcinomas. Recent clinical evidence shows improved therapeutic outcomes through optimized CAR architectures and preconditioning regimens, with objective response rates demonstrating progressive enhancement across successive clinical trial generations. The discussion addresses ongoing limitations regarding treatment durability and manufacturing consistency while exploring emerging solutions such as synthetic biology approaches and multi-omics guided antigen selection. By integrating preclinical insights with translational clinical data, this work establishes a strategic framework for advancing adoptive T-cell therapies in gynecologic oncology, emphasizing the synergistic potential of combining CAR-T technology with personalized neoantigen vaccines and microenvironment-reprogramming agents. These collective advances underscore the transformative prospects of engineered T-cell immunotherapies while providing actionable strategies to overcome the unique biological barriers inherent to female reproductive tract malignancies. T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves genetically reprogramming T lymphocytes to recognize tumor-specific antigens, has shown clinical success in hematologic malignancies and is expanding its potential in solid tumors. Gynecological cancers, including ovarian, cervical, and endometrial carcinomas, present persistent therapeutic challenges due to their aggressive recurrence patterns and limited responses to conventional therapies in advanced disease stages. This review offers a comprehensive analysis of CAR-T cell therapy advancements in gynecologic oncology, examining fundamental biological mechanisms of tumor-immune interactions, clinical progress in target antigen validation, and innovative approaches to counter immunosuppressive tumor microenvironments. Key challenges specific to these malignancies are discussed, such as molecular heterogeneity in endometrial tumors, ascites-mediated T-cell dysfunction in ovarian cancer (OC), and viral antigen dynamics in HPV- driven cervical carcinomas. Recent clinical evidence shows improved therapeutic outcomes through optimized CAR architectures and preconditioning regimens, with objective response rates demonstrating progressive enhancement across successive clinical trial generations. The discussion addresses ongoing limitations regarding treatment durability and manufacturing consistency while exploring emerging solutions such as synthetic biology approaches and multi-omics guided antigen selection. By integrating preclinical insights with translational clinical data, this work establishes a strategic framework for advancing adoptive T-cell therapies in gynecologic oncology, emphasizing the synergistic potential of combining CAR-T technology with personalized neoantigen vaccines and microenvironment-reprogramming agents. These collective advances underscore the transformative prospects of engineered T-cell immunotherapies while providing actionable strategies to overcome the unique biological barriers inherent to female reproductive tract malignancies.T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves genetically reprogramming T lymphocytes to recognize tumor-specific antigens, has shown clinical success in hematologic malignancies and is expanding its potential in solid tumors. Gynecological cancers, including ovarian, cervical, and endometrial carcinomas, present persistent therapeutic challenges due to their aggressive recurrence patterns and limited responses to conventional therapies in advanced disease stages. This review offers a comprehensive analysis of CAR-T cell therapy advancements in gynecologic oncology, examining fundamental biological mechanisms of tumor-immune interactions, clinical progress in target antigen validation, and innovative approaches to counter immunosuppressive tumor microenvironments. Key challenges specific to these malignancies are discussed, such as molecular heterogeneity in endometrial tumors, ascites-mediated T-cell dysfunction in ovarian cancer (OC), and viral antigen dynamics in HPV- driven cervical carcinomas. Recent clinical evidence shows improved therapeutic outcomes through optimized CAR architectures and preconditioning regimens, with objective response rates demonstrating progressive enhancement across successive clinical trial generations. The discussion addresses ongoing limitations regarding treatment durability and manufacturing consistency while exploring emerging solutions such as synthetic biology approaches and multi-omics guided antigen selection. By integrating preclinical insights with translational clinical data, this work establishes a strategic framework for advancing adoptive T-cell therapies in gynecologic oncology, emphasizing the synergistic potential of combining CAR-T technology with personalized neoantigen vaccines and microenvironment-reprogramming agents. These collective advances underscore the transformative prospects of engineered T-cell immunotherapies while providing actionable strategies to overcome the unique biological barriers inherent to female reproductive tract malignancies. Abstract T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves genetically reprogramming T lymphocytes to recognize tumor-specific antigens, has shown clinical success in hematologic malignancies and is expanding its potential in solid tumors. Gynecological cancers, including ovarian, cervical, and endometrial carcinomas, present persistent therapeutic challenges due to their aggressive recurrence patterns and limited responses to conventional therapies in advanced disease stages. This review offers a comprehensive analysis of CAR-T cell therapy advancements in gynecologic oncology, examining fundamental biological mechanisms of tumor-immune interactions, clinical progress in target antigen validation, and innovative approaches to counter immunosuppressive tumor microenvironments. Key challenges specific to these malignancies are discussed, such as molecular heterogeneity in endometrial tumors, ascites-mediated T-cell dysfunction in ovarian cancer (OC), and viral antigen dynamics in HPV- driven cervical carcinomas. Recent clinical evidence shows improved therapeutic outcomes through optimized CAR architectures and preconditioning regimens, with objective response rates demonstrating progressive enhancement across successive clinical trial generations. The discussion addresses ongoing limitations regarding treatment durability and manufacturing consistency while exploring emerging solutions such as synthetic biology approaches and multi-omics guided antigen selection. By integrating preclinical insights with translational clinical data, this work establishes a strategic framework for advancing adoptive T-cell therapies in gynecologic oncology, emphasizing the synergistic potential of combining CAR-T technology with personalized neoantigen vaccines and microenvironment-reprogramming agents. These collective advances underscore the transformative prospects of engineered T-cell immunotherapies while providing actionable strategies to overcome the unique biological barriers inherent to female reproductive tract malignancies. Graphic abstract T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR) T-cell therapy, which involves genetically reprogramming T lymphocytes to recognize tumor-specific antigens, has shown clinical success in hematologic malignancies and is expanding its potential in solid tumors. Gynecological cancers, including ovarian, cervical, and endometrial carcinomas, present persistent therapeutic challenges due to their aggressive recurrence patterns and limited responses to conventional therapies in advanced disease stages. This review offers a comprehensive analysis of CAR-T cell therapy advancements in gynecologic oncology, examining fundamental biological mechanisms of tumor-immune interactions, clinical progress in target antigen validation, and innovative approaches to counter immunosuppressive tumor microenvironments. Key challenges specific to these malignancies are discussed, such as molecular heterogeneity in endometrial tumors, ascites-mediated T-cell dysfunction in ovarian cancer (OC), and viral antigen dynamics in HPV- driven cervical carcinomas. Recent clinical evidence shows improved therapeutic outcomes through optimized CAR architectures and preconditioning regimens, with objective response rates demonstrating progressive enhancement across successive clinical trial generations. The discussion addresses ongoing limitations regarding treatment durability and manufacturing consistency while exploring emerging solutions such as synthetic biology approaches and multi-omics guided antigen selection. By integrating preclinical insights with translational clinical data, this work establishes a strategic framework for advancing adoptive T-cell therapies in gynecologic oncology, emphasizing the synergistic potential of combining CAR-T technology with personalized neoantigen vaccines and microenvironment-reprogramming agents. These collective advances underscore the transformative prospects of engineered T-cell immunotherapies while providing actionable strategies to overcome the unique biological barriers inherent to female reproductive tract malignancies. Graphic abstract Keywords: Immunotherapy, T cell, CAR-T cell therapy, Gynecological malignancies, Tumor microenvironment |
| ArticleNumber | 207 |
| Audience | Academic |
| Author | Zhao, Xi Ran, Jialing Chen, Jinxin Li, Shenglong |
| Author_xml | – sequence: 1 givenname: Xi surname: Zhao fullname: Zhao, Xi – sequence: 2 givenname: Jialing surname: Ran fullname: Ran, Jialing – sequence: 3 givenname: Shenglong surname: Li fullname: Li, Shenglong – sequence: 4 givenname: Jinxin surname: Chen fullname: Chen, Jinxin |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/40713697$$D View this record in MEDLINE/PubMed |
| BookMark | eNptkktr3DAUhU1JaR7tH-iiGLrpxqmuJEvWqgyhbQKBQknX4loPR8GWppYnYf59NZk0ZCAIodfRx7nSOa2OYoquqj4COQfoxNcMVHHWENqWzgGahzfVCXApGt6q7ujF_Lg6zfmOEJCd5O-qY04kMKHkSfV7Ze8xGpdrjLZOfV7QjGWVfH1TGzeOTY_Z2TpM0yam5dbNuN7WIdbDNjqTxjQEg2M94RiGWEDB5ffVW49jdh-exrPqz4_vNxeXzfWvn1cXq-vG8E4tTTGvKLUt4QIdJ2CKUY_QoncArWQeuTGEcGPBY-csSg5eOdUTwnrKKDurrvZcm_BOr-cw4bzVCYN-3EjzoHFeQilHW7S-bdF5YQpFtr20wlpfLHgGyKCwvu1Z600_OWtcXGYcD6CHJzHc6iHda6BUyZaqQvjyRJjT343Li55C3j0gRpc2WRfDTKlOgCjSz3vpgMVbiD4VpNnJ9arjilEh-K6881dUpVk3BVOS4EPZP7jw6WUNz-b_f3YR0L3AzCnn2flnCRC9S5TeJ0qXROnHROkH9g8q0731 |
| Cites_doi | 10.1016/j.canlet.2024.216805 10.1038/s41590-024-02015-4 10.1038/s41388-023-02918-w 10.1186/s40425-019-0742-6 10.1016/j.ccell.2022.10.016 10.1186/s12951-024-03005-2 10.1136/jitc-2024-010528 10.1007/s00262-022-03238-w 10.1016/S1470-2045(19)30541-8 10.1097/CJI.0000000000000160 10.1038/s41392-024-01824-1 10.1186/s13046-023-02798-8 10.1001/jamaoncol.2024.6797 10.1016/j.omto.2021.02.013 10.1016/j.bbcan.2025.189292 10.1136/bmj-2024-080978 10.1186/s12943-024-01981-5 10.1200/JCO.23.01771 10.1016/S1470-2045(24)00088-3 10.1136/jitc-2021-003959 10.1093/neuonc/noy084 10.1016/j.ymthe.2025.03.005 10.1016/j.annonc.2021.11.013 10.1136/jitc-2019-000188 10.1016/S1470-2045(24)00674-0 10.1126/science.abm0594 10.1158/2159-8290.CD-23-0101 10.1136/jitc-2024-009058 10.1016/j.ymthe.2025.03.052 10.1200/JCO.21.02067 10.1016/j.medj.2025.100669 10.1126/scitranslmed.adr8941 10.1136/jitc-2021-002682 10.1038/s41590-025-02113-x 10.1007/s00262-023-03529-w 10.1172/jci.insight.99488 10.1146/annurev-immunol-082423-040557 10.1186/s12964-024-01834-0 10.7150/thno.100555 10.1016/S0140-6736(24)01808-7 10.1093/neuonc/noae177 10.1001/jamanetworkopen.2020.13201 10.1016/j.omto.2021.01.002 10.1056/NEJMoa2404512 10.1186/s12967-024-05846-9 10.1016/j.cell.2023.06.002 10.1038/s41392-025-02124-y 10.1073/pnas.1611481113 10.1016/j.ccell.2024.03.001 10.1038/s41416-018-0313-5 10.1136/jitc-2024-009404 10.1056/NEJMc2501311 10.1200/JCO.23.00092 10.1016/j.annonc.2024.07.727 10.3389/fimmu.2024.1305810 10.1097/JS9.0000000000002175 10.1038/s41598-024-51217-1 10.1016/j.ccell.2025.03.032 10.1007/s40265-023-01934-0 10.1016/j.ymthe.2024.06.029 10.1016/j.semcancer.2022.02.008 10.1158/2159-8290.CD-19-0790 10.1002/advs.202406328 10.1126/sciimmunol.adf4726 10.1002/cac2.12587 10.1038/s41392-024-02029-2 10.1186/s12943-025-02253-6 10.1016/j.immuni.2023.09.005 10.1136/jitc-2023-008662 10.1038/s41571-024-00977-w 10.1158/1078-0432.CCR-16-1433 10.3390/cancers16020333 10.1038/s41591-024-02942-7 10.1126/scitranslmed.adp0675 10.1016/j.lanepe.2024.101157 10.1200/JCO.23.00914 10.1038/s41571-023-00826-2 10.1016/j.immuni.2023.09.011 10.1056/NEJMoa1500596 10.1056/NEJMoa2401726 10.1056/NEJMoa2311926 10.1016/j.jconrel.2021.05.034 10.1038/s41577-023-00937-y 10.1056/NEJMoa2402604 10.1038/s41418-023-01229-7 10.1056/NEJMoa2215530 10.1158/1078-0432.CCR-24-2469 10.1158/0008-5472.CAN-09-4299 10.1136/jitc-2024-011230 10.1016/j.ccell.2019.02.006 10.1016/j.arr.2025.102715 10.1038/s41587-024-02446-2 10.1038/s41392-022-01270-x 10.1038/s41571-024-00984-x 10.1016/j.ccell.2024.07.002 10.1200/JCO.24.00646 10.1016/S0140-6736(24)02722-3 10.1200/JCO.23.02625 10.1016/j.it.2021.09.002 10.1038/s41423-024-01224-z 10.1016/j.ebiom.2021.103409 10.1016/j.ccell.2023.07.011 10.1001/jamaoncol.2023.0197 10.1038/s41571-024-00937-4 10.1136/jitc-2024-010739 10.1172/jci.insight.122311 10.1038/s41392-023-01646-7 10.1136/jitc-2022-006533 10.1016/S1470-2045(24)00437-6 10.1186/s13046-021-02139-7 10.1186/s12943-024-01972-6 10.3322/caac.70008 10.1016/j.ymthe.2017.01.011 10.1158/2326-6066.CIR-19-0258 10.1016/j.addr.2024.115306 10.1016/j.ccell.2025.03.006 10.1002/advs.201903301 10.1016/j.ccell.2021.10.011 10.1016/j.ccell.2024.08.007 10.1093/annonc/mdz135 10.1038/s41568-024-00705-7 10.1016/j.ccell.2024.06.015 10.1016/j.annonc.2025.04.001 10.1016/j.trecan.2019.06.004 10.1016/j.annonc.2025.01.015 10.1002/advs.202104452 10.1016/j.ymthe.2019.11.028 10.1016/j.cell.2024.06.013 10.1016/j.cmet.2024.12.013 10.1038/s43018-023-00668-y 10.1158/0008-5472.CAN-20-2701 10.1056/NEJMoa2211437 10.1158/1078-0432.CCR-24-0071 10.3389/fimmu.2021.768115 10.1038/s41571-024-00934-7 10.1016/j.trecan.2024.03.010 10.1016/j.jaci.2025.04.005 10.1186/s12943-023-01844-5 10.1038/s41591-024-03411-x 10.1172/jci.insight.142513 10.1021/acsami.0c15239 10.1002/ctm2.1416 10.1016/j.ccell.2025.03.019 10.1038/s41467-024-51337-2 10.1124/pharmrev.124.001070 10.1158/0008-5472.CAN-19-0880 10.1001/jama.2024.19462 10.1186/s12967-023-04271-8 10.1016/S0140-6736(22)00562-1 10.1126/sciimmunol.abk0957 10.1016/S1470-2045(24)00592-8 10.1016/S1470-2045(24)00192-X 10.1016/j.drup.2025.101215 10.1002/adhm.202401927 10.1038/s41586-024-08071-y 10.1136/jitc-2024-009563 10.1186/s12943-025-02294-x 10.1038/s41573-024-01098-w 10.1186/s13045-024-01581-2 10.1038/s41575-025-01062-y 10.1158/2326-6066.CIR-19-0315 10.1016/j.immuni.2023.08.014 10.1158/1078-0432.CCR-23-3296 10.1038/s41467-019-09263-1 10.1038/s41375-025-02574-x 10.1186/s12967-022-03480-x 10.1080/2162402X.2019.1665460 10.1016/j.ctrv.2024.102790 10.1016/S0140-6736(24)01756-2 10.1136/jitc-2023-006863 10.1158/1078-0432.CCR-24-0606 10.1080/2162402X.2016.1249561 10.1186/s12967-015-0460-x 10.1038/s41467-023-40850-5 10.1016/j.annonc.2024.10.828 10.1038/s41568-024-00761-z 10.1200/JCO-24-02589 10.1016/j.annonc.2024.07.723 10.1007/s11547-024-01899-4 10.1200/JCO.19.00739 10.1016/j.jaci.2018.10.054 10.1038/s41591-021-01462-y 10.1016/j.scib.2025.03.054 10.1016/j.tcb.2020.12.001 10.3389/fimmu.2021.738958 10.1080/2162402X.2015.1026529 10.1200/JCO-24-02081 10.1056/NEJMoa2407417 10.1186/s13058-023-01684-7 10.1002/cam4.3337 10.1056/NEJMoa2112435 10.1016/j.biopha.2022.114057 10.1186/s13045-025-01690-6 10.1038/s41577-025-01161-6 10.1038/s41568-024-00785-5 |
| ContentType | Journal Article |
| Copyright | 2025. The Author(s). COPYRIGHT 2025 BioMed Central Ltd. The Author(s) 2025 2025 |
| Copyright_xml | – notice: 2025. The Author(s). – notice: COPYRIGHT 2025 BioMed Central Ltd. – notice: The Author(s) 2025 2025 |
| DBID | AAYXX CITATION CGR CUY CVF ECM EIF NPM 7X8 5PM DOA |
| DOI | 10.1186/s12943-025-02411-w |
| DatabaseName | CrossRef Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic PubMed Central (Full Participant titles) DOAJ Directory of Open Access Journals |
| DatabaseTitle | CrossRef MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: DOA name: DOAJ Directory of Open Access Journals url: https://www.doaj.org/ sourceTypes: Open Website – sequence: 2 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 3 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Biology |
| EISSN | 1476-4598 |
| EndPage | 25 |
| ExternalDocumentID | oai_doaj_org_article_dadf55aef6c74175b7d6ddf129f31a31 PMC12297529 A849326642 40713697 10_1186_s12943_025_02411_w |
| Genre | Journal Article Review |
| GrantInformation_xml | – fundername: Natural Science Foundation of Liaoning Province grantid: 2023JH2/101700177 |
| GroupedDBID | --- 0R~ 123 29M 2WC 53G 5VS 7X7 88E 8FI 8FJ AAFWJ AAJSJ AASML AAYXX ABDBF ABUWG ACGFO ACGFS ACIHN ACIWK ACMJI ACPRK ACUHS ADBBV ADRAZ ADUKV AEAQA AENEX AFKRA AFPKN AFRAH AHBYD AHMBA AHYZX ALIPV ALMA_UNASSIGNED_HOLDINGS AMKLP AMTXH AOIJS BAPOH BAWUL BCNDV BENPR BFQNJ BMC BPHCQ BVXVI C6C CCPQU CITATION CS3 DIK DU5 E3Z EAD EAP EAS EBD EBLON EBS EMB EMK EMOBN ESX F5P FYUFA GROUPED_DOAJ GX1 HH5 HMCUK HYE IAO IHR INH INR ITC KQ8 LGEZI LOTEE M1P M~E NADUK NXXTH O5R O5S OK1 OVT P2P PGMZT PHGZM PHGZT PIMPY PJZUB PPXIY PQQKQ PROAC PSQYO PZZ RBZ RNS ROL RPM RSV SBL SOJ SV3 TR2 TUS UKHRP W2D WOQ WOW XSB CGR CUY CVF ECM EIF NPM 7X8 5PM PUEGO |
| ID | FETCH-LOGICAL-c489t-129922d5046ae401c459fa15afe11573fa4cc004cd1fa8eda741f9e9b003b2323 |
| IEDL.DBID | DOA |
| ISSN | 1476-4598 |
| IngestDate | Wed Aug 27 01:21:31 EDT 2025 Thu Aug 21 18:24:37 EDT 2025 Mon Jul 28 18:32:21 EDT 2025 Wed Jul 30 23:55:41 EDT 2025 Tue Jul 29 03:42:15 EDT 2025 Fri Aug 01 03:41:26 EDT 2025 Thu Aug 07 07:14:04 EDT 2025 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Gynecological malignancies Tumor microenvironment Immunotherapy T cell CAR-T cell therapy |
| Language | English |
| License | 2025. The Author(s). Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc-nd/4.0/. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c489t-129922d5046ae401c459fa15afe11573fa4cc004cd1fa8eda741f9e9b003b2323 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 ObjectType-Review-3 content type line 23 |
| OpenAccessLink | https://doaj.org/article/dadf55aef6c74175b7d6ddf129f31a31 |
| PMID | 40713697 |
| PQID | 3233998616 |
| PQPubID | 23479 |
| PageCount | 25 |
| ParticipantIDs | doaj_primary_oai_doaj_org_article_dadf55aef6c74175b7d6ddf129f31a31 pubmedcentral_primary_oai_pubmedcentral_nih_gov_12297529 proquest_miscellaneous_3233998616 gale_infotracmisc_A849326642 gale_infotracacademiconefile_A849326642 pubmed_primary_40713697 crossref_primary_10_1186_s12943_025_02411_w |
| PublicationCentury | 2000 |
| PublicationDate | 2025-07-26 |
| PublicationDateYYYYMMDD | 2025-07-26 |
| PublicationDate_xml | – month: 07 year: 2025 text: 2025-07-26 day: 26 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England – name: London |
| PublicationTitle | Molecular cancer |
| PublicationTitleAlternate | Mol Cancer |
| PublicationYear | 2025 |
| Publisher | BioMed Central Ltd BioMed Central BMC |
| Publisher_xml | – name: BioMed Central Ltd – name: BioMed Central – name: BMC |
| References | PD Katsikis (2411_CR26) 2024; 24 I Raphael (2411_CR110) 2025; 17 I Diaconu (2411_CR183) 2017; 25 J Liu (2411_CR173) 2024; 22 SM Norberg (2411_CR42) 2023; 41 F Baettig (2411_CR193) 2019; 7 V Kannen (2411_CR138) 2024; 588 M Gore (2411_CR12) 2025; 1880 YZ Wang (2411_CR16) 2024; 15 2411_CR93 CJ Wu (2411_CR130) 2024; 43 NM Tannir (2411_CR91) 2024; 35 U Uslu (2411_CR46) 2024; 42 MJ Pittet (2411_CR60) 2023; 56 D Lorusso (2411_CR92) 2024; 404 S Gaillard (2411_CR2) 2025; 43 TK Burki (2411_CR111) 2019; 20 S Martin-Lluesma (2411_CR29) 2024; 35 K Wang (2411_CR70) 2024; 42 SL Wang (2411_CR24) 2025; 43 X Zhu (2411_CR35) 2025; 37 CF Friedman (2411_CR84) 2024; 30 E Ghisoni (2411_CR83) 2024; 21 LK Berry (2411_CR117) 2024; 22 R Dummer (2411_CR33) 2025; 31 R Kristeleit (2411_CR97) 2025; 11 G Galliverti (2411_CR199) 2020; 8 A Awadasseid (2411_CR17) 2023; 157 RW Naumann (2411_CR94) 2019; 37 HL MacGregor (2411_CR116) 2019; 8 N Xie (2411_CR27) 2023; 8 T Mondal (2411_CR106) 2023; 30 M Koneru (2411_CR148) 2015; 13 SS Mun (2411_CR175) 2023; 72 SL Topalian (2411_CR36) 2023; 41 UA Matulonis (2411_CR96) 2019; 30 A Hrvat (2411_CR172) 2023; 42 JL Tanyi (2411_CR149) 2017; 40 V Garg (2411_CR8) 2023; 83 RY Huang (2411_CR185) 2017; 6 H Shi (2411_CR137) 2024; 10 L Bergmann (2411_CR90) 2025 G Xue (2411_CR71) 2024; 42 JA How (2411_CR18) 2024; 21 Y Cao (2411_CR140) 2019; 10 JD Wolchok (2411_CR88) 2025; 392 2411_CR129 2411_CR121 2411_CR122 M Tao (2411_CR9) 2021; 40 S Peng (2411_CR136) 2024; 23 S Cheng (2411_CR120) 2020; 7 NM Ratnam (2411_CR124) 2019; 21 Z Peng (2411_CR99) 2024; 25 L Zhang (2411_CR176) 2020; 3 J Liu (2411_CR34) 2024; 9 P Gupta (2411_CR171) 2022; 9 E Schoutrop (2411_CR107) 2021; 81 B Du (2411_CR39) 2025; 43 2411_CR139 2411_CR132 2411_CR133 2411_CR135 KG Anderson (2411_CR128) 2019; 7 L Yu (2411_CR127) 2021; 12 R Shu (2411_CR152) 2021; 20 J Duerinck (2411_CR72) 2024; 26 N Chuangchot (2411_CR177) 2023; 25 R Fu (2411_CR195) 2024; 9 Q Dang (2411_CR57) 2024; 23 LM Chambers (2411_CR4) 2025; 36 2411_CR108 J Li (2411_CR41) 2023; 22 R Porret (2411_CR109) 2025; 17 2411_CR102 AA Francoeur (2411_CR14) 2025; 22 T May (2411_CR3) 2024; 25 J St Laurent (2411_CR5) 2024; 42 V Bhandarkar (2411_CR168) 2025; 10 P Harter (2411_CR100) 2025; 36 WR Huang (2411_CR20) 2025; 111 JN Brudno (2411_CR45) 2024; 332 U Uslu (2411_CR48) 2025; 43 AJ Anandappa (2411_CR123) 2020; 10 Y Feng (2411_CR53) 2024; 22 H Zhao (2411_CR143) 2023; 21 SE Cena (2411_CR15) 2024; 129 2411_CR119 EK Lee (2411_CR191) 2019; 5 N Kumar (2411_CR153) 2022; 86 MB Ward (2411_CR103) 2025; 77 X Zhai (2411_CR31) 2025; 18 2411_CR1 AM Holder (2411_CR28) 2024; 24 K Itahashi (2411_CR165) 2022; 7 DL Richardson (2411_CR6) 2023; 9 GF Fleming (2411_CR13) 2023; 41 2411_CR23 R Nadal (2411_CR82) 2024; 21 I Vergote (2411_CR7) 2022; 33 S Goswami (2411_CR37) 2024; 25 Y Choi (2411_CR64) 2024; 209 2411_CR166 W Cheng (2411_CR25) 2024; 17 J Trillo-Tinoco (2411_CR169) 2019; 79 A Rodriguez-Garcia (2411_CR181) 2020; 28 2411_CR164 XF Liu (2411_CR186) 2016; 113 2411_CR10 2411_CR19 Y Wang (2411_CR105) 2023; 8 BC Creelan (2411_CR38) 2021; 27 2411_CR174 L Ma (2411_CR49) 2023; 186 NL Berinstein (2411_CR115) 2015; 4 S Dong (2411_CR32) 2025; 81 2411_CR47 2411_CR40 2411_CR43 PJ de Vos (2411_CR112) 2010; 70 2411_CR147 S Basnet (2411_CR131) 2024; 32 I Mellman (2411_CR58) 2023; 56 Y Zhao (2411_CR65) 2024; 30 2411_CR144 2411_CR145 PT Le (2411_CR162) 2021; 12 2411_CR146 Y Lee (2411_CR62) 2025; 14 2411_CR141 Q Chen (2411_CR197) 2025; 12 L Zhang (2411_CR68) 2025; 24 PL Swiecicki (2411_CR79) 2025; 43 C Zhu (2411_CR52) 2024; 33 S Qi (2411_CR104) 2025; 107 2411_CR159 KJC Galpin (2411_CR134) 2024; 14 SM Hwang (2411_CR170) 2024; 635 JJ Luke (2411_CR77) 2022; 399 W Sun (2411_CR63) 2024; 44 2411_CR157 2411_CR151 A Jay (2411_CR118) 2025; 26 L Liu (2411_CR142) 2022; 20 J Zhang (2411_CR156) 2021; 68 A Ghasemi (2411_CR182) 2024; 5 AA Sarnaik (2411_CR44) 2024; 42 C Luri-Rey (2411_CR113) 2025; 25 2411_CR66 2411_CR67 A Dudeck (2411_CR154) 2019; 144 2411_CR69 Y Tang (2411_CR167) 2024; 21 C Xia (2411_CR194) 2021; 335 DT Le (2411_CR98) 2015; 372 M Falcaro (2411_CR11) 2025; 49 A Salmon (2411_CR22) 2024; 129 Q Zhang (2411_CR178) 2021; 20 M Hamieh (2411_CR50) 2023; 13 2411_CR56 JD Spicer (2411_CR76) 2024; 404 AB Apolo (2411_CR81) 2025; 392 F Uhlitz (2411_CR189) 2021; 39 YK Chae (2411_CR192) 2024; 30 JG Rurik (2411_CR54) 2022; 375 P Wawrzyniak (2411_CR30) 2025; 24 A Xiong (2411_CR75) 2025; 405 D Hanahan (2411_CR160) 2025; 25 G Pascual-Pasto (2411_CR51) 2024; 15 A Monette (2411_CR179) 2025; 31 TR McCaw (2411_CR161) 2021; 10 2411_CR80 2411_CR190 F Guan (2411_CR114) 2025; 10 CS Lo (2411_CR125) 2017; 23 2411_CR89 2411_CR86 A Oaknin (2411_CR95) 2024; 25 LF Somarribas Patterson (2411_CR61) 2021; 42 M Kreileder (2411_CR155) 2021; 31 A Santhosh (2411_CR87) 2025; 392 BR Corr (2411_CR21) 2025; 388 AM Oza (2411_CR101) 2025; 26 2411_CR187 2411_CR188 SB Hansen (2411_CR196) 2024; 14 2411_CR184 M Provencio (2411_CR74) 2023; 3896 JR Giles (2411_CR59) 2023; 56 K Mulati (2411_CR126) 2019; 120 S Viel (2411_CR158) 2025; 24 2411_CR78 J Chen (2411_CR150) 2023; 72 2411_CR73 Z Xiao (2411_CR55) 2023; 14 Z Luo (2411_CR180) 2020; 12 Y Gao (2411_CR163) 2023; 13 2411_CR198 PH Luo (2411_CR85) 2024; 42 |
| References_xml | – volume: 588 start-page: 216805 year: 2024 ident: 2411_CR138 publication-title: Cancer Lett doi: 10.1016/j.canlet.2024.216805 – volume: 25 start-page: 2186 issue: 12 year: 2024 ident: 2411_CR37 publication-title: Nat Immunol doi: 10.1038/s41590-024-02015-4 – volume: 43 start-page: 511 issue: 7 year: 2024 ident: 2411_CR130 publication-title: Oncogene doi: 10.1038/s41388-023-02918-w – volume: 7 start-page: 281 issue: 1 year: 2019 ident: 2411_CR193 publication-title: J Immunother Cancer doi: 10.1186/s40425-019-0742-6 – volume: 41 start-page: 58 issue: 1 year: 2023 ident: 2411_CR42 publication-title: Cancer Cell doi: 10.1016/j.ccell.2022.10.016 – volume: 22 start-page: 737 issue: 1 year: 2024 ident: 2411_CR53 publication-title: J Nanobiotechnol doi: 10.1186/s12951-024-03005-2 – ident: 2411_CR66 doi: 10.1136/jitc-2024-010528 – volume: 72 start-page: 409 issue: 2 year: 2023 ident: 2411_CR150 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-022-03238-w – volume: 20 start-page: e474 issue: 9 year: 2019 ident: 2411_CR111 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(19)30541-8 – volume: 40 start-page: 104 issue: 3 year: 2017 ident: 2411_CR149 publication-title: J Immunother doi: 10.1097/CJI.0000000000000160 – volume: 9 start-page: 118 issue: 1 year: 2024 ident: 2411_CR195 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-024-01824-1 – volume: 42 start-page: 235 issue: 1 year: 2023 ident: 2411_CR172 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-023-02798-8 – volume: 11 start-page: 377 issue: 4 year: 2025 ident: 2411_CR97 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2024.6797 – volume: 20 start-page: 556 year: 2021 ident: 2411_CR178 publication-title: Mol Ther Oncolytics doi: 10.1016/j.omto.2021.02.013 – volume: 1880 start-page: 189292 issue: 2 year: 2025 ident: 2411_CR12 publication-title: Biochim Biophys Acta Rev Cancer doi: 10.1016/j.bbcan.2025.189292 – volume: 388 start-page: e080978 year: 2025 ident: 2411_CR21 publication-title: BMJ doi: 10.1136/bmj-2024-080978 – volume: 23 start-page: 72 issue: 1 year: 2024 ident: 2411_CR57 publication-title: Mol Cancer doi: 10.1186/s12943-024-01981-5 – volume: 42 start-page: 127 issue: 2 year: 2024 ident: 2411_CR5 publication-title: J Clin Oncol doi: 10.1200/JCO.23.01771 – volume: 25 start-page: 588 issue: 5 year: 2024 ident: 2411_CR95 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00088-3 – ident: 2411_CR122 doi: 10.1136/jitc-2021-003959 – volume: 21 start-page: 37 issue: 1 year: 2019 ident: 2411_CR124 publication-title: Neuro Oncol doi: 10.1093/neuonc/noy084 – ident: 2411_CR144 doi: 10.1016/j.ymthe.2025.03.005 – volume: 33 start-page: 276 issue: 3 year: 2022 ident: 2411_CR7 publication-title: Ann Oncol doi: 10.1016/j.annonc.2021.11.013 – ident: 2411_CR141 doi: 10.1136/jitc-2019-000188 – volume: 26 start-page: 249 issue: 2 year: 2025 ident: 2411_CR101 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00674-0 – volume: 375 start-page: 91 issue: 6576 year: 2022 ident: 2411_CR54 publication-title: Science doi: 10.1126/science.abm0594 – volume: 13 start-page: 829 issue: 4 year: 2023 ident: 2411_CR50 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-23-0101 – ident: 2411_CR135 doi: 10.1136/jitc-2024-009058 – ident: 2411_CR147 doi: 10.1016/j.ymthe.2025.03.052 – ident: 2411_CR190 doi: 10.1200/JCO.21.02067 – ident: 2411_CR69 doi: 10.1016/j.medj.2025.100669 – volume: 17 start-page: eadr8941 issue: 790 year: 2025 ident: 2411_CR109 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.adr8941 – ident: 2411_CR121 doi: 10.1136/jitc-2021-002682 – volume: 26 start-page: 544 issue: 4 year: 2025 ident: 2411_CR118 publication-title: Nat Immunol doi: 10.1038/s41590-025-02113-x – volume: 72 start-page: 3773 issue: 11 year: 2023 ident: 2411_CR175 publication-title: Cancer Immunol Immunother doi: 10.1007/s00262-023-03529-w – ident: 2411_CR139 doi: 10.1172/jci.insight.99488 – ident: 2411_CR166 doi: 10.1146/annurev-immunol-082423-040557 – volume: 22 start-page: 459 issue: 1 year: 2024 ident: 2411_CR173 publication-title: Cell Commun Signal doi: 10.1186/s12964-024-01834-0 – volume: 14 start-page: 6913 issue: 18 year: 2024 ident: 2411_CR196 publication-title: Theranostics doi: 10.7150/thno.100555 – volume: 404 start-page: 1321 issue: 10460 year: 2024 ident: 2411_CR92 publication-title: Lancet doi: 10.1016/S0140-6736(24)01808-7 – volume: 26 start-page: 2208 issue: 12 year: 2024 ident: 2411_CR72 publication-title: Neuro Oncol doi: 10.1093/neuonc/noae177 – volume: 3 start-page: e2013201 issue: 8 year: 2020 ident: 2411_CR176 publication-title: JAMA Netw Open doi: 10.1001/jamanetworkopen.2020.13201 – volume: 20 start-page: 325 year: 2021 ident: 2411_CR152 publication-title: Mol Ther Oncolytics doi: 10.1016/j.omto.2021.01.002 – ident: 2411_CR23 doi: 10.1056/NEJMoa2404512 – volume: 22 start-page: 1048 issue: 1 year: 2024 ident: 2411_CR117 publication-title: J Transl Med doi: 10.1186/s12967-024-05846-9 – volume: 186 start-page: 3148 issue: 15 year: 2023 ident: 2411_CR49 publication-title: Cell doi: 10.1016/j.cell.2023.06.002 – volume: 10 start-page: 93 issue: 1 year: 2025 ident: 2411_CR114 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-025-02124-y – volume: 113 start-page: 10666 issue: 38 year: 2016 ident: 2411_CR186 publication-title: Proc Natl Acad Sci U S A doi: 10.1073/pnas.1611481113 – volume: 42 start-page: 780 issue: 5 year: 2024 ident: 2411_CR71 publication-title: Cancer Cell doi: 10.1016/j.ccell.2024.03.001 – volume: 120 start-page: 115 issue: 1 year: 2019 ident: 2411_CR126 publication-title: Br J Cancer doi: 10.1038/s41416-018-0313-5 – ident: 2411_CR164 doi: 10.1136/jitc-2024-009404 – volume: 392 start-page: 1245 issue: 12 year: 2025 ident: 2411_CR87 publication-title: N Engl J Med doi: 10.1056/NEJMc2501311 – volume: 41 start-page: 4603 issue: 29 year: 2023 ident: 2411_CR13 publication-title: J Clin Oncol doi: 10.1200/JCO.23.00092 – volume: 35 start-page: 1026 issue: 11 year: 2024 ident: 2411_CR91 publication-title: Ann Oncol doi: 10.1016/j.annonc.2024.07.727 – volume: 15 start-page: 1305810 year: 2024 ident: 2411_CR16 publication-title: Front Immunol doi: 10.3389/fimmu.2024.1305810 – volume: 111 start-page: 2208 issue: 2 year: 2025 ident: 2411_CR20 publication-title: Int J Surg doi: 10.1097/JS9.0000000000002175 – volume: 14 start-page: 787 issue: 1 year: 2024 ident: 2411_CR134 publication-title: Sci Rep doi: 10.1038/s41598-024-51217-1 – ident: 2411_CR108 doi: 10.1016/j.ccell.2025.03.032 – volume: 83 start-page: 1365 issue: 15 year: 2023 ident: 2411_CR8 publication-title: Drugs doi: 10.1007/s40265-023-01934-0 – volume: 32 start-page: 3114 issue: 9 year: 2024 ident: 2411_CR131 publication-title: Mol Ther doi: 10.1016/j.ymthe.2024.06.029 – volume: 86 start-page: 513 issue: Pt 3 year: 2022 ident: 2411_CR153 publication-title: Semin Cancer Biol doi: 10.1016/j.semcancer.2022.02.008 – volume: 10 start-page: 185 issue: 2 year: 2020 ident: 2411_CR123 publication-title: Cancer Discov doi: 10.1158/2159-8290.CD-19-0790 – volume: 12 start-page: e2406328 issue: 2 year: 2025 ident: 2411_CR197 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.202406328 – volume: 10 start-page: eadf4726 issue: 103 year: 2025 ident: 2411_CR168 publication-title: Sci Immunol doi: 10.1126/sciimmunol.adf4726 – volume: 44 start-page: 1071 issue: 9 year: 2024 ident: 2411_CR63 publication-title: Cancer Commun (Lond) doi: 10.1002/cac2.12587 – volume: 9 start-page: 318 issue: 1 year: 2024 ident: 2411_CR34 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-024-02029-2 – volume: 24 start-page: 119 issue: 1 year: 2025 ident: 2411_CR68 publication-title: Mol Cancer doi: 10.1186/s12943-025-02253-6 – volume: 56 start-page: 2231 issue: 10 year: 2023 ident: 2411_CR59 publication-title: Immunity doi: 10.1016/j.immuni.2023.09.005 – ident: 2411_CR67 doi: 10.1136/jitc-2023-008662 – volume: 22 start-page: 182 issue: 3 year: 2025 ident: 2411_CR14 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-024-00977-w – volume: 23 start-page: 925 issue: 4 year: 2017 ident: 2411_CR125 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-16-1433 – ident: 2411_CR151 doi: 10.3390/cancers16020333 – volume: 30 start-page: 1330 issue: 5 year: 2024 ident: 2411_CR84 publication-title: Nat Med doi: 10.1038/s41591-024-02942-7 – volume: 17 start-page: eadp0675 issue: 790 year: 2025 ident: 2411_CR110 publication-title: Sci Transl Med doi: 10.1126/scitranslmed.adp0675 – volume: 49 start-page: 101157 year: 2025 ident: 2411_CR11 publication-title: Lancet Reg Health Eur doi: 10.1016/j.lanepe.2024.101157 – ident: 2411_CR86 doi: 10.1200/JCO.23.00914 – volume: 21 start-page: 8 issue: 1 year: 2024 ident: 2411_CR82 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-023-00826-2 – volume: 56 start-page: 2188 issue: 10 year: 2023 ident: 2411_CR58 publication-title: Immunity doi: 10.1016/j.immuni.2023.09.011 – volume: 372 start-page: 2509 issue: 26 year: 2015 ident: 2411_CR98 publication-title: N Engl J Med doi: 10.1056/NEJMoa1500596 – volume: 392 start-page: 45 issue: 1 year: 2025 ident: 2411_CR81 publication-title: N Engl J Med doi: 10.1056/NEJMoa2401726 – ident: 2411_CR73 doi: 10.1056/NEJMoa2311926 – volume: 335 start-page: 557 year: 2021 ident: 2411_CR194 publication-title: J Control Release doi: 10.1016/j.jconrel.2021.05.034 – volume: 24 start-page: 213 issue: 3 year: 2024 ident: 2411_CR26 publication-title: Nat Rev Immunol doi: 10.1038/s41577-023-00937-y – ident: 2411_CR89 doi: 10.1056/NEJMoa2402604 – volume: 30 start-page: 2408 issue: 11 year: 2023 ident: 2411_CR106 publication-title: Cell Death Differ doi: 10.1038/s41418-023-01229-7 – volume: 3896 start-page: 504 year: 2023 ident: 2411_CR74 publication-title: N Engl J Med doi: 10.1056/NEJMoa2215530 – volume: 31 start-page: 439 issue: 3 year: 2025 ident: 2411_CR179 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-24-2469 – volume: 70 start-page: 2707 issue: 7 year: 2010 ident: 2411_CR112 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-09-4299 – ident: 2411_CR133 doi: 10.1136/jitc-2024-011230 – ident: 2411_CR187 doi: 10.1016/j.ccell.2019.02.006 – volume: 107 start-page: 102715 year: 2025 ident: 2411_CR104 publication-title: Ageing Res Rev doi: 10.1016/j.arr.2025.102715 – volume: 43 start-page: 506 issue: 4 year: 2025 ident: 2411_CR48 publication-title: Nat Biotechnol doi: 10.1038/s41587-024-02446-2 – volume: 8 start-page: 9 issue: 1 year: 2023 ident: 2411_CR27 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-022-01270-x – ident: 2411_CR43 doi: 10.1038/s41571-024-00984-x – volume: 42 start-page: 1319 issue: 8 year: 2024 ident: 2411_CR46 publication-title: Cancer Cell doi: 10.1016/j.ccell.2024.07.002 – volume: 43 start-page: 578 issue: 5 year: 2025 ident: 2411_CR79 publication-title: J Clin Oncol doi: 10.1200/JCO.24.00646 – volume: 405 start-page: 839 issue: 10481 year: 2025 ident: 2411_CR75 publication-title: Lancet doi: 10.1016/S0140-6736(24)02722-3 – ident: 2411_CR80 doi: 10.1200/JCO.23.02625 – volume: 42 start-page: 975 issue: 11 year: 2021 ident: 2411_CR61 publication-title: Trends Immunol doi: 10.1016/j.it.2021.09.002 – volume: 21 start-page: 1215 issue: 11 year: 2024 ident: 2411_CR167 publication-title: Cell Mol Immunol doi: 10.1038/s41423-024-01224-z – volume: 68 start-page: 103409 year: 2021 ident: 2411_CR156 publication-title: EBioMedicine doi: 10.1016/j.ebiom.2021.103409 – volume: 41 start-page: 1551 issue: 9 year: 2023 ident: 2411_CR36 publication-title: Cancer Cell doi: 10.1016/j.ccell.2023.07.011 – volume: 9 start-page: 851 issue: 6 year: 2023 ident: 2411_CR6 publication-title: JAMA Oncol doi: 10.1001/jamaoncol.2023.0197 – volume: 21 start-page: 801 issue: 11 year: 2024 ident: 2411_CR83 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-024-00937-4 – ident: 2411_CR198 doi: 10.1136/jitc-2024-010739 – ident: 2411_CR157 doi: 10.1172/jci.insight.122311 – volume: 8 start-page: 399 issue: 1 year: 2023 ident: 2411_CR105 publication-title: Signal Transduct Target Ther doi: 10.1038/s41392-023-01646-7 – ident: 2411_CR56 doi: 10.1136/jitc-2022-006533 – volume: 25 start-page: 1288 issue: 10 year: 2024 ident: 2411_CR99 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00437-6 – volume: 40 start-page: 338 issue: 1 year: 2021 ident: 2411_CR9 publication-title: J Exp Clin Cancer Res doi: 10.1186/s13046-021-02139-7 – volume: 23 start-page: 58 issue: 1 year: 2024 ident: 2411_CR136 publication-title: Mol Cancer doi: 10.1186/s12943-024-01972-6 – ident: 2411_CR1 doi: 10.3322/caac.70008 – volume: 25 start-page: 580 issue: 3 year: 2017 ident: 2411_CR183 publication-title: Mol Ther doi: 10.1016/j.ymthe.2017.01.011 – volume: 7 start-page: 1412 issue: 9 year: 2019 ident: 2411_CR128 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-19-0258 – volume: 209 start-page: 115306 year: 2024 ident: 2411_CR64 publication-title: Adv Drug Deliv Rev doi: 10.1016/j.addr.2024.115306 – volume: 43 start-page: 641 issue: 4 year: 2025 ident: 2411_CR24 publication-title: Cancer Cell doi: 10.1016/j.ccell.2025.03.006 – volume: 7 start-page: 1903301 issue: 7 year: 2020 ident: 2411_CR120 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.201903301 – volume: 39 start-page: 1567 issue: 12 year: 2021 ident: 2411_CR189 publication-title: Cancer Cell doi: 10.1016/j.ccell.2021.10.011 – volume: 42 start-page: 1582 issue: 9 year: 2024 ident: 2411_CR70 publication-title: Cancer Cell doi: 10.1016/j.ccell.2024.08.007 – volume: 30 start-page: 1080 issue: 7 year: 2019 ident: 2411_CR96 publication-title: Ann Oncol doi: 10.1093/annonc/mdz135 – volume: 24 start-page: 498 issue: 7 year: 2024 ident: 2411_CR28 publication-title: Nat Rev Cancer doi: 10.1038/s41568-024-00705-7 – volume: 42 start-page: 1315 issue: 8 year: 2024 ident: 2411_CR44 publication-title: Cancer Cell doi: 10.1016/j.ccell.2024.06.015 – ident: 2411_CR102 doi: 10.1016/j.annonc.2025.04.001 – volume: 5 start-page: 524 issue: 9 year: 2019 ident: 2411_CR191 publication-title: Trends Cancer doi: 10.1016/j.trecan.2019.06.004 – volume: 36 start-page: 244 issue: 3 year: 2025 ident: 2411_CR4 publication-title: Ann Oncol doi: 10.1016/j.annonc.2025.01.015 – volume: 9 start-page: e2104452 issue: 14 year: 2022 ident: 2411_CR171 publication-title: Adv Sci (Weinh) doi: 10.1002/advs.202104452 – volume: 28 start-page: 548 issue: 2 year: 2020 ident: 2411_CR181 publication-title: Mol Ther doi: 10.1016/j.ymthe.2019.11.028 – ident: 2411_CR10 doi: 10.1016/j.cell.2024.06.013 – volume: 37 start-page: 806 issue: 4 year: 2025 ident: 2411_CR35 publication-title: Cell Metab doi: 10.1016/j.cmet.2024.12.013 – volume: 5 start-page: 240 issue: 2 year: 2024 ident: 2411_CR182 publication-title: Nat Cancer doi: 10.1038/s43018-023-00668-y – volume: 81 start-page: 3022 issue: 11 year: 2021 ident: 2411_CR107 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-20-2701 – ident: 2411_CR78 doi: 10.1056/NEJMoa2211437 – ident: 2411_CR184 doi: 10.1158/1078-0432.CCR-24-0071 – volume: 12 start-page: 768115 year: 2021 ident: 2411_CR127 publication-title: Front Immunol doi: 10.3389/fimmu.2021.768115 – volume: 21 start-page: 781 issue: 11 year: 2024 ident: 2411_CR18 publication-title: Nat Rev Clin Oncol doi: 10.1038/s41571-024-00934-7 – volume: 10 start-page: 610 issue: 7 year: 2024 ident: 2411_CR137 publication-title: Trends Cancer doi: 10.1016/j.trecan.2024.03.010 – ident: 2411_CR145 doi: 10.1016/j.jaci.2025.04.005 – volume: 22 start-page: 141 issue: 1 year: 2023 ident: 2411_CR41 publication-title: Mol Cancer doi: 10.1186/s12943-023-01844-5 – ident: 2411_CR188 doi: 10.1172/jci.insight.99488 – volume: 31 start-page: 144 issue: 1 year: 2025 ident: 2411_CR33 publication-title: Nat Med doi: 10.1038/s41591-024-03411-x – ident: 2411_CR174 doi: 10.1172/jci.insight.142513 – volume: 12 start-page: 56712 issue: 51 year: 2020 ident: 2411_CR180 publication-title: ACS Appl Mater Interfaces doi: 10.1021/acsami.0c15239 – volume: 13 start-page: e1416 issue: 9 year: 2023 ident: 2411_CR163 publication-title: Clin Transl Med doi: 10.1002/ctm2.1416 – volume: 43 start-page: 665 issue: 4 year: 2025 ident: 2411_CR39 publication-title: Cancer Cell doi: 10.1016/j.ccell.2025.03.019 – volume: 15 start-page: 7141 issue: 1 year: 2024 ident: 2411_CR51 publication-title: Nat Commun doi: 10.1038/s41467-024-51337-2 – volume: 77 start-page: 100011 issue: 1 year: 2025 ident: 2411_CR103 publication-title: Pharmacol Rev doi: 10.1124/pharmrev.124.001070 – volume: 79 start-page: 5034 issue: 19 year: 2019 ident: 2411_CR169 publication-title: Cancer Res doi: 10.1158/0008-5472.CAN-19-0880 – volume: 332 start-page: 1924 issue: 22 year: 2024 ident: 2411_CR45 publication-title: JAMA doi: 10.1001/jama.2024.19462 – volume: 21 start-page: 596 issue: 1 year: 2023 ident: 2411_CR143 publication-title: J Transl Med doi: 10.1186/s12967-023-04271-8 – volume: 399 start-page: 1718 issue: 10336 year: 2022 ident: 2411_CR77 publication-title: Lancet doi: 10.1016/S0140-6736(22)00562-1 – volume: 7 start-page: eabk0957 issue: 76 year: 2022 ident: 2411_CR165 publication-title: Sci Immunol doi: 10.1126/sciimmunol.abk0957 – volume: 25 start-page: 1509 issue: 12 year: 2024 ident: 2411_CR3 publication-title: Lancet Oncol doi: 10.1016/S1470-2045(24)00592-8 – ident: 2411_CR19 doi: 10.1016/S1470-2045(24)00192-X – volume: 81 start-page: 101215 year: 2025 ident: 2411_CR32 publication-title: Drug Resist Updat doi: 10.1016/j.drup.2025.101215 – volume: 33 start-page: 377 year: 2024 ident: 2411_CR52 publication-title: Bioact Mater – volume: 14 start-page: e2401927 issue: 1 year: 2025 ident: 2411_CR62 publication-title: Adv Healthc Mater doi: 10.1002/adhm.202401927 – volume: 635 start-page: 1010 issue: 8040 year: 2024 ident: 2411_CR170 publication-title: Nature doi: 10.1038/s41586-024-08071-y – volume-title: Interdisciplinary renal cell carcinoma working group of the, prospective randomised Phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal year: 2025 ident: 2411_CR90 – ident: 2411_CR132 doi: 10.1136/jitc-2024-009563 – volume: 24 start-page: 89 issue: 1 year: 2025 ident: 2411_CR30 publication-title: Mol Cancer doi: 10.1186/s12943-025-02294-x – volume: 24 start-page: 190 issue: 3 year: 2025 ident: 2411_CR158 publication-title: Nat Rev Drug Discov doi: 10.1038/s41573-024-01098-w – volume: 17 start-page: 54 issue: 1 year: 2024 ident: 2411_CR25 publication-title: J Hematol Oncol doi: 10.1186/s13045-024-01581-2 – ident: 2411_CR40 doi: 10.1038/s41575-025-01062-y – volume: 8 start-page: 131 issue: 1 year: 2020 ident: 2411_CR199 publication-title: Cancer Immunol Res doi: 10.1158/2326-6066.CIR-19-0315 – volume: 56 start-page: 2218 issue: 10 year: 2023 ident: 2411_CR60 publication-title: Immunity doi: 10.1016/j.immuni.2023.08.014 – volume: 30 start-page: 5527 issue: 24 year: 2024 ident: 2411_CR65 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-23-3296 – volume: 10 start-page: 1280 issue: 1 year: 2019 ident: 2411_CR140 publication-title: Nat Commun doi: 10.1038/s41467-019-09263-1 – ident: 2411_CR146 doi: 10.1038/s41375-025-02574-x – volume: 20 start-page: 280 issue: 1 year: 2022 ident: 2411_CR142 publication-title: J Transl Med doi: 10.1186/s12967-022-03480-x – volume: 8 start-page: e1665460 issue: 12 year: 2019 ident: 2411_CR116 publication-title: Oncoimmunology doi: 10.1080/2162402X.2019.1665460 – volume: 129 start-page: 102790 year: 2024 ident: 2411_CR22 publication-title: Cancer Treat Rev doi: 10.1016/j.ctrv.2024.102790 – volume: 404 start-page: 1240 issue: 10459 year: 2024 ident: 2411_CR76 publication-title: Lancet doi: 10.1016/S0140-6736(24)01756-2 – ident: 2411_CR129 doi: 10.1136/jitc-2023-006863 – volume: 30 start-page: 5593 issue: 24 year: 2024 ident: 2411_CR192 publication-title: Clin Cancer Res doi: 10.1158/1078-0432.CCR-24-0606 – volume: 6 start-page: e1249561 issue: 1 year: 2017 ident: 2411_CR185 publication-title: Oncoimmunology doi: 10.1080/2162402X.2016.1249561 – volume: 13 start-page: 102 year: 2015 ident: 2411_CR148 publication-title: J Transl Med doi: 10.1186/s12967-015-0460-x – volume: 14 start-page: 5110 issue: 1 year: 2023 ident: 2411_CR55 publication-title: Nat Commun doi: 10.1038/s41467-023-40850-5 – volume: 36 start-page: 185 issue: 2 year: 2025 ident: 2411_CR100 publication-title: Ann Oncol doi: 10.1016/j.annonc.2024.10.828 – volume: 25 start-page: 41 issue: 1 year: 2025 ident: 2411_CR160 publication-title: Nat Rev Cancer doi: 10.1038/s41568-024-00761-z – volume: 43 start-page: 868 issue: 7 year: 2025 ident: 2411_CR2 publication-title: J Clin Oncol doi: 10.1200/JCO-24-02589 – volume: 35 start-page: 860 issue: 10 year: 2024 ident: 2411_CR29 publication-title: Ann Oncol doi: 10.1016/j.annonc.2024.07.723 – volume: 129 start-page: 1906 issue: 12 year: 2024 ident: 2411_CR15 publication-title: Radiol Med doi: 10.1007/s11547-024-01899-4 – volume: 37 start-page: 2825 issue: 31 year: 2019 ident: 2411_CR94 publication-title: J Clin Oncol doi: 10.1200/JCO.19.00739 – volume: 144 start-page: S4 issue: 4S year: 2019 ident: 2411_CR154 publication-title: J Allergy Clin Immunol doi: 10.1016/j.jaci.2018.10.054 – volume: 27 start-page: 1410 issue: 8 year: 2021 ident: 2411_CR38 publication-title: Nat Med doi: 10.1038/s41591-021-01462-y – ident: 2411_CR119 doi: 10.1016/j.scib.2025.03.054 – volume: 31 start-page: 224 issue: 3 year: 2021 ident: 2411_CR155 publication-title: Trends Cell Biol doi: 10.1016/j.tcb.2020.12.001 – volume: 12 start-page: 738958 year: 2021 ident: 2411_CR162 publication-title: Front Immunol doi: 10.3389/fimmu.2021.738958 – volume: 4 start-page: e1026529 issue: 8 year: 2015 ident: 2411_CR115 publication-title: Oncoimmunology doi: 10.1080/2162402X.2015.1026529 – ident: 2411_CR47 doi: 10.1200/JCO-24-02081 – volume: 392 start-page: 11 issue: 1 year: 2025 ident: 2411_CR88 publication-title: N Engl J Med doi: 10.1056/NEJMoa2407417 – volume: 25 start-page: 86 issue: 1 year: 2023 ident: 2411_CR177 publication-title: Breast Cancer Res doi: 10.1186/s13058-023-01684-7 – volume: 10 start-page: 709 issue: 2 year: 2021 ident: 2411_CR161 publication-title: Cancer Med doi: 10.1002/cam4.3337 – ident: 2411_CR93 doi: 10.1056/NEJMoa2112435 – volume: 157 start-page: 114057 year: 2023 ident: 2411_CR17 publication-title: Biomed Pharmacother doi: 10.1016/j.biopha.2022.114057 – volume: 18 start-page: 37 issue: 1 year: 2025 ident: 2411_CR31 publication-title: J Hematol Oncol doi: 10.1186/s13045-025-01690-6 – ident: 2411_CR159 doi: 10.1038/s41577-025-01161-6 – volume: 42 start-page: 1596 issue: 13 year: 2024 ident: 2411_CR85 publication-title: J Clin Oncol – volume: 25 start-page: 249 issue: 4 year: 2025 ident: 2411_CR113 publication-title: Nat Rev Cancer doi: 10.1038/s41568-024-00785-5 |
| SSID | ssj0017874 |
| Score | 2.4403474 |
| SecondaryResourceType | review_article |
| Snippet | T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor (CAR)... Abstract T cell-mediated immunotherapy has revolutionized oncology by enabling precision immune responses against malignant cells. Chimeric Antigen Receptor... |
| SourceID | doaj pubmedcentral proquest gale pubmed crossref |
| SourceType | Open Website Open Access Repository Aggregation Database Index Database |
| StartPage | 207 |
| SubjectTerms | Animals Antigens, Neoplasm - immunology Cancer CAR-T cell therapy Cervical cancer Development and progression Female Genital Neoplasms, Female - etiology Genital Neoplasms, Female - immunology Genital Neoplasms, Female - therapy Gynecological malignancies Health aspects Humans Immune response Immunotherapy Immunotherapy - methods Immunotherapy, Adoptive - adverse effects Immunotherapy, Adoptive - methods Ovarian cancer Papillomavirus infections Receptors, Chimeric Antigen - immunology Review Sex discrimination against women T cell T cells T-Lymphocytes - immunology T-Lymphocytes - metabolism Tumor antigens Tumor microenvironment Tumor Microenvironment - immunology Viral antigens |
| Title | Advances and obstacles of T cell-based immunotherapy in gynecological malignancies |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/40713697 https://www.proquest.com/docview/3233998616 https://pubmed.ncbi.nlm.nih.gov/PMC12297529 https://doaj.org/article/dadf55aef6c74175b7d6ddf129f31a31 |
| Volume | 24 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Nb9QwEB1BEYgLgvIVKCsjIXFAUXFiO8kxRa2qlVqh0kp7s_zZ7oEsYreq9t8zEyfVRhy4cFop9sF-Y3tmdvyeAT4F0kiznJi_mKsKa_ActNHlxtbWRqlK7ogofHauTq_EfCEXO0990Z2wJA-cgDv0xkcpTYjKofOrpK288j6im4olNz2DukCfNyZTQ_0Al6EYKTK1Olxjd0H1ShqT4Dy_m7ihXq3_7zN5xylNL0zueKCT5_BsCB1Zm4b8Ah6Ebh8ep8ckt_vw5Gwok7-EizZV9tfMdJ6tLEaAdPmNrSK7ZPRXfU7Oy7MlkUMGCtaWLTt2ve2CG49D9hNj9Ov0fO_6FVydHF9-O82HxxNyJ-pmk-OMm6LwEvNfEzCJckI20XBpYiB9nTIa4RzuEOd5NHXwBtGNTSCJxNJimFW-hr1u1YW3wCpX1Iobbj0FgMY01VdMC0uirEpnfcjgy4il_pU0MnSfW9RKJ-Q1Iq975PVdBkcE931P0rfuP6DV9WB1_S-rZ_CZjKVpF6JFnBnIBDhg0rPSbS0oMMXkKoODSU_cPW7S_HE0t6YmunLWhdXtWiMEGLzhxFUGb5L578dMWXCpmiqDerIwJpOatnTLm168mxfEZS6ad_8DhvfwtOgXdZUX6gD2Nr9vwwcMkjZ2Bg-rRTWDR207_zHH36Pj8-8Xs36X_AEw8RPt |
| linkProvider | Directory of Open Access Journals |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Advances+and+obstacles+of+T+cell-based+immunotherapy+in+gynecological+malignancies&rft.jtitle=Molecular+cancer&rft.au=Zhao%2C+Xi&rft.au=Ran%2C+Jialing&rft.au=Li%2C+Shenglong&rft.au=Chen%2C+Jinxin&rft.date=2025-07-26&rft.issn=1476-4598&rft.eissn=1476-4598&rft.volume=24&rft.issue=1&rft_id=info:doi/10.1186%2Fs12943-025-02411-w&rft.externalDBID=n%2Fa&rft.externalDocID=10_1186_s12943_025_02411_w |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1476-4598&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1476-4598&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1476-4598&client=summon |